For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit

Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy

Clinical Trial Details

This randomized phase III trial studies radiation therapy with chemotherapy to see how well it works compared to radiation therapy alone in treating patients with stage I or stage II cervical cancer who previously underwent surgery. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation therapy together with chemotherapy is more effective than radiation therapy alone in treating patients with cervical cancer.

Key Eligibility: 
  • Primary cervical cancer I-IIA with squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma initially treated with a standard radical hyseterctomy with pelvic lymphadenectomy 
  • Tumor cannot be in the parametria, pelvic lymph nodes or any other extra uterine site or with positive surgical margins 
  • No cervix cancer with previous radiation or chemotherapy
  • Detailed eligibility reviewed when you contact the study team

Study contact by location



Lina Flores, RN
(718) 965-9859

Primary Investigator(s)

Protocol ID(s)



Open to Enrollment

Age Group